PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of aacPermissionsJournals.ASM.orgJournalAAC ArticleJournal InfoAuthorsReviewers
 
Antimicrob Agents Chemother. 2012 September; 56(9): 4951–4954.
PMCID: PMC3421891

Molecular Identification and In Vitro Response to Antifungal Drugs of Clinical Isolates of Exserohilum

Abstract

Exserohilum is an agent of human and animal mycoses. Although classification has been based on a few subtle morphological differences, three species of clinical interest have been traditionally accepted. In this study, by using a multigene sequence analysis, we have demonstrated that Exserohilum longirostratum and E. mcginnisii are probable synonyms of E. rostratum. The isolates tested were mainly from the nasal region. Antifungal susceptibility testing demonstrated high activity of the eight agents tested against this fungus.

TEXT

The anamorphic genus Exserohilum (teleomorph Setosphaeria, family Pleosporaceae, order Pleosporales) is comprised of approximately 35 species, which are common saprobic fungi on plant debris, although some cause infections in plants, animals, and humans (1, 9, 10, 23, 24). Although these fungi have a broad geographical distribution, human infections occur predominantly in tropical and subtropical regions, affecting mainly immunocompetent patients (1). Exserohilum causes mainly allergic sinusitis, keratitis, and, less frequently, endocarditis, endophthalmitis, peritonitis, and invasive infections affecting brain, bones, lungs, and urinary tract (7, 21, 22). Three species, E. rostratum, E. longirostratum, and E. mcginnisii, have been reported as opportunistic pathogens for humans (1, 3, 19, 22). These species are characterized by quick growth, forming dark colonies, geniculate conidiophores, and ellipsoid to fusiform, straight to curved, multidistoseptate conidia with a protruding hilum. Such species can be mainly differentiated by the conidial morphology (7, 17).

To assess the incidence of Exserohilum species in clinical samples, we have identified morphologically and molecularly a set of isolates from different clinical specimens, which were sent to a reference laboratory during a period of 7 years (2003 to 2009) from different regions of the United States for identification and/or antifungal susceptibility testing.

A total of 34 clinical isolates, presumably belonging to Exserohilum spp., was received in the Fungus Testing Laboratory of the University of Texas Health Science Center at San Antonio, and some type or reference strains were included in the present study. The majority of the isolates were from the nasal region (47%), followed by cutaneous and subcutaneous infections (20.5%) and ocular infections (14.7%). The remaining 11.6% of the isolates were from abscesses, blood, bronchoalveolar lavage fluid, and lumbar disc, while 6.2% were of unknown origin (Table 1). The fungi were cultured on potato carrot agar (PCA) and oatmeal agar (OA).

Table 1
Clinical isolates and type and reference strains of Exserohilum spp. included in the studya

The internal transcribed spacer (ITS) region and the 28S ribosomal DNA (rDNA) (D1/D2), actin (ACT), and elongation factor 1-alpha (EF-1α) genes were amplified and sequenced following previously described protocols (4, 18, 25).

The in vitro activity of eight antifungal agents (amphotericin B, itraconazole, posaconazole, voriconazole, anidulafungin, caspofungin, micafungin, and terbinafine) against the isolates tested was evaluated according to reference guidelines (6). Paecilomyces variotii ATCC MYA-3630 was used as a quality control strain.

All the isolates examined displayed the typical features of the genus Exserohilum (24). Thirty-two isolates showed straight or slightly curved conidia, which were ellipsoidal to fusiform or rostrate, with smooth to finely roughened walls and brown to olivaceous brown coloring, measuring 25 to 91 by 9 to 22 μm, with 4 to 9 distosepta and dark bands at both ends, and were identified as E. rostratum. Two isolates were identified as E. longirostratum, due to the presence of markedly larger conidia (up to 228 by 12 to 19 μm), which had 6 to 16 distosepta and were centrally curved (7, 24). The type strain of E. mcginnisii was examined and showed straight, cylindrical, or slightly clavate conidia, which were smooth-walled and brown, measuring 44 to 76 by 11 to 18 μm, with 4 to 8 distosepta and without dark bands at both ends (7, 17).

With the primers used, we were able to amplify and sequence 392 to 411, 317 to 318, 464, and 609 bp of the ITS, ACT, D1/D2, and EF-1α loci, respectively. Sequences of the four regions obtained from the 37 isolates (34 clinical isolates and 3 type or reference strains) included in the study were analyzed phylogenetically. Comparison of such sequences unequivocally proved that all the isolates tested belonged to a single species (Table 2), which demonstrated that E. longirostratum and E. mcginnissii are synonyms of E. rostratum.

Table 2
Percentages of similarity among type and reference strains of the three clinically relevant Exserohilum speciesa

In general, all the antifungal drugs tested showed relatively low MICs against Exserohilum isolates, with only a few exceptions for echinocandins. Caspofungin and micafungin showed relatively high MICs against seven isolates and anidulafungin against one (Table 3).

Table 3
Results of in vitro antifungal susceptibility testing for 34 clinical isolates of Exserohilum rostratuma

Some studies have clearly demonstrated the ability of Exserohilum to cause humans infections, although they are mainly single case reports where the fungal identification was based exclusively on morphological criteria (7). This is the first study in which a large panel of Exserohilum clinical isolates from different anatomical sites has been identified using phenotypic and genetic criteria. The anatomical sites from where the fungi were isolated agree with those reported in previous studies (8, 15, 20, 21).

Exserohilum species are mainly identified by the conidial morphology seen when growing in the natural substratum (24). In vitro identification is more difficult, the conidia tending to be smaller and the isolates losing the ability to sporulate (17, 24). In this study, all the isolates grew well in the media used, although they sporulated better on PCA than on OA. However, the conidia never reached the maximum length described for any of those species in the natural substrate.

Previous taxonomic and molecular studies suggested that E. rostratum and E. longirostratum could be the same species (7, 13, 14). The present study proved through a multilocus analysis that all isolates, including the type strain of E. mcginnisii and reference strains of E. longirostratum, showed a high homology with the type strain of E. rostratum, indicating that all are probable conspecific species. However, further studies sequencing additional genes are required to demonstrate such synonymy. In vitro antifungal susceptibility data for Exserohilum spp. are very variable; however, they are scarce and, in general, are from studies performed before the standardization of the procedures for antifungal susceptibility testing for molds (2, 5, 11, 12, 16). The high in vitro activity of all the antifungals tested here against Exserohilum is remarkable, although it is unknown how this can be translated to clinical practice. Data on the clinical treatment of infections by Exserohilum are also very scarce, but recent reviews of cases of sinusitis and cutaneous infections by these fungi report successful outcomes with amphotericin B and more recently with itraconazole and voriconazole (8, 15).

ACKNOWLEDGMENTS

This work was supported by the Spanish Ministerio de Ciencia e Innovación (grant CGL 2011-27185/BOS).

We are indebted to the curators of the Centraalbureau voor Schimmelcultures (the Netherlands) and of the Institut Pasteur (France) for supplying many of the strains used in the study.

We have no conflicts of interest to declare.

We alone are responsible for the content and writing of this paper.

Footnotes

Published ahead of print 25 June 2012

REFERENCES

1. Adler A, et al. 2006. Exserohilum: an emerging human pathogen. Eur. J. Clin. Microbiol. Infect. Dis. 25:247–253. [PubMed]
2. Agarwal A, Singh SM. 1995. A case of cutaneous phaeohyphomycosis caused by Exserohilum, its in vitro sensitivity and review of literature. Mycopathologia 131:9–12 doi:10.1007/BF01103898. [PubMed]
3. Al-Attar A, Williams CG, Redett R. 2006. Rare lower extremity invasive fungal infection in an immunosuppressed patient: Exserohilum longirostratum. Plast. Reconstr. Surg. 117:44e–47e. [PubMed]
4. Alvarez E, et al. 2010. Molecular phylogenetic diversity of the emerging mucoralean fungus Apophysomyces: proposal of three new species. Rev. Iberoam. Micol. 27:80–89. [PubMed]
5. Arredondo-García JL, Amábile Cuevas CF., RedMic2 Study Group 2009. Susceptibility of Mexican isolates of yeasts and moulds to amphotericin B and triazole antifungals. J. Infect. Dev. Ctries. 3:398–401. [PubMed]
6. Clinical and Laboratory Standards Institute 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard, 2nd ed Document M38-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
7. de Hoog GS, Guarro J, Gené Figueras JMJ. 2000. Atlas of clinical fungi, 2nd ed Centraalbureau voor Schimmelcultures, Utrecht, the Netherlands.
8. Derber C, Elam K, Bearman G. 2010. Invasive sinonasal disease due to dematiaceous fungi in immunocompromised individuals: case report and review of the literature. Int. J. Infect. Dis. 14(Suppl. 3):e329–e332. [PubMed]
9. Ellis MB. 1971. Dematiaceous hyphomycetes. Commonwealth Mycological Institute, Kew, United Kingdom.
10. Ellis MB. 1976. More dematiaceous hyphomycetes. Commonwealth Mycological Institute, Kew, United Kingdom.
11. Fung-Tomc JC, et al. 1995. In vitro antifungal and fungicidal spectra of a new pradimicin derivative, BMS-181184. Antimicrob. Agents Chemother. 39:295–300 doi:10.1128/AAC.39.2.295. [PMC free article] [PubMed]
12. Jessup CJ, Ryder NS, Ghannoum MA. 2000. An evaluation of the in vitro activity of terbinafine. Med. Mycol. 38:155–159. [PubMed]
13. Lau A, et al. 2007. Development and clinical application of a panfungal PCR assay to detect and identify fungal DNA in tissue specimens. J. Clin. Microbiol. 45:380–385. [PMC free article] [PubMed]
14. Leonard KJ, Suggs EG. 1974. Setosphaeria prolata, the ascigerous state of Exserohilum prolatum. Mycologia 66:281–297 doi:10.2307/3758363.
15. Lin SC, Sun PL, Ju YM, Chan YJ. 2009. Cutaneous phaeohyphomycosis caused by Exserohilum rostratum in a patient with cutaneous T-cell lymphoma. Int. J. Dermatol. 48:295–298. [PubMed]
16. McGinnis MR, Pasarell L. 1998. In vitro evaluation of terbinafine and itraconazole against dematiaceous fungi. Med. Mycol. 36:243–246. [PubMed]
17. McGinnis MR, Rinaldi MG, Winn RE. 1986. Emerging agents of phaeohyphomycosis: pathogenic species of Bipolaris and Exserohilum. J. Clin. Microbiol. 24:250–259. [PMC free article] [PubMed]
18. Mugambi GK, Huhndorf SM. 2009. Molecular phylogenetics of Pleosporales: Melanommataceae and Lophiostomataceae re-circumscribed (Pleosporomycetidae, Dothideomycetes, Ascomycota). Stud. Mycol. 64:103–121. [PMC free article] [PubMed]
19. Padhye AA, Ajello L, Wieden MA, Steinbronn KK. 1986. Phaeohyphomycosis of the nasal sinuses caused by a new species of Exserohilum. J. Clin. Microbiol. 24:245–249. [PMC free article] [PubMed]
20. Peerapur BV, Rao SD, Patil S, Mantur BG. 2004. Keratomycosis due to Exserohilum rostratum—a case report. Indian J. Med. Microbiol. 22:126–127. [PubMed]
21. Revankar SG, Sutton DA. 2010. Melanized fungi in human disease. Clin. Microbiol. Rev. 23:884–928. [PMC free article] [PubMed]
22. Saint-Jean M, St-Germain G, Laferrière C, Tapiero B. 2007. Hospital acquired phaeohyphomycosis due to Exserohilum rostratum in a child with leukemia. Can. J. Infect. Dis. Med. Microbiol. 18:200–202. [PMC free article] [PubMed]
23. Sivanesan A. 1984. The bitunicate ascomycetes and their anamorphs. J. Cramer, Vaduz, Liechtenstein.
24. Sivanesan A. 1987. Graminicolous species of Bipolaris, Curvularia, Drechslera, Exserohilum and their teleomorphs. Mycol. Pap. 158:1–261.
25. Voigt K, Wöstemeyer J. 2000. Reliable amplification of actin genes facilitates deep-level phylogeny. Microbiol. Res. 155:179–195. [PubMed]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)